Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise [Yahoo! Finance]
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) is now covered by analysts at Maxim Group. They set a "buy" rating and a $2.00 price target on the stock.
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 [Yahoo! Finance]
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024